Purpose: COVID-19 is the result of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infection, which was first isolated and identified in a patient in Wuhan. Although viral pathogenesis is not yet fully known, viral infection is thought to be cytopathic to airway epithelial cells and alveolar cells. In addition, similar to SARS-COV, immune-mediated damage is thought to play a critical role in the pathogenesis of COVID-19. In most patients, the disease progresses with mild to moderate symptoms. The most common findings; symptoms of upper respiratory tract infection including fever, dry cough, malaise, headache, sore throat and myalgia. 20% of the patients show signs of severe lung damage. In the diagnosis of COVID-19, Polymerase Chain Reaction (PCR), serological examination, imaging methods and routine laboratory tests are used. It is thought that determination of laboratory parameters for the diagnosis of COVID-19 will help in the diagnosis, early isolation and early treatment of suspicious cases. Therefore, it was aimed to evaluate complete blood count and biochemical parameters in patient and healthy control groups. Materials and Methods: Fifty patients who applied to the COVID-19 outpatient clinic with early-stage complaints and had a positive PCR test and 50 healthy individuals were included in the study. Biochemical parameters were evaluated retrospectively. 17th edition of SPSS Statistics (IBM Corporation, Somers, NY) software was used for the statistical analysis. Results: A significant difference was found between the patient and control groups in terms of lymphocyte count, monocyte count and CRP parameters. While the lymphocyte count was lower in the patient group, the monocyte count and CRP levels were found to be higher. Conclusion: In line with the data we have obtained; It is considered that especially lymphocyte and monocyte count, CRP values can provide support in terms of diagnosis and follow-up of patients presenting with mild symptoms.
Amaç: COVİD- 19 ilk kez Wuhan’da bir hastada izole edilen ve tanımlanan Şiddetli Akut Solunum Sendromu Coronavirus 2 (SARS-CoV-2) virüs enfeksiyonun sonucudur. Viral patogenez henüz tam olarak bilinmiyor olmakla birlikte, viral enfeksiyonun hava yolu epitel hücrelerine ve alveoler hücrelere sitopatik olduğu düşünülmektedir. Ayrıca SARS-COV’a benzer şekilde immün aracılı hasar da COVİD- 19’un patogenezinde kritik rol oynadığı düşünülmektedir. Çoğu hastada hastalık hafif–orta düzeyde semptomlarla seyreder. En sık bulgular; ateş, kuru öksürük, kırgınlık, baş ağrısı, boğaz ağrısı ve miyaljiyi içeren üst solunum yolu enfeksiyonu bulgularıdır. Hastaların %20’si ağır akciğer hasarı bulguları gösterir. COVİD- 19’da tanıda Polimeraz Zincir Reaksiyonu (PCR), serolojik inceleme, görüntüleme metodları ve rutin laboratuvar tetkikleri kullanılır. COVİD-19 tanısına yönelik laboratuvar parametrelerinin belirlenmesinin şüpheli vakaların tanınması, erken izolasyonu ve erken tedavisine yardımcı olacağı düşünülmektedir. Bu nedenle, hasta ve sağlıklı kontrol gruplarında tam kan sayımı ve biyokimyasal parametreler değerlendirilmesi amaçlandı. Materyal ve Metot: Çalışmaya COVİD-19 polikliniğine erken evre şikayetlerle başvuran, PCR testi pozitif olan 50 hasta ve 50 sağlıklı birey dahil edildi. Biyokimyasal parametreler retrospektif olarak değerlendirildi. İstatistik analiz; SPSS Statistics (IBM Corporation, Somers, NY) yazılımının 17. sürülümü ile yapıldı. Bulgular: Lenfosit sayısı, monosit sayısı ve CRP parametreleri açısından hasta ve kontrol grubu arasında anlamlı farklılık bulundu. Lenfosit sayısı hasta grubunda daha düşük seyrederken, monosit sayısı ve CRP düzeylerinin daha yüksek olduğu belirlendi. Sonuç: Elde ettiğimiz veriler doğrultusunda; hafif semptomlarla başvuran hastalarda özellikle lenfosit ve monosit sayısı, CRP değerlerinin tanı ve hastaların takibi açısından destek sağlayabileceği değerlendirilmektedir.
Primary Language | Turkish |
---|---|
Subjects | Health Care Administration |
Journal Section | Articles |
Authors | |
Publication Date | December 15, 2021 |
Submission Date | June 30, 2021 |
Acceptance Date | September 7, 2021 |
Published in Issue | Year 2021 Volume: 14 Issue: 3 |
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.